HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope: drug may shield breast cancer patients from dangerous side effect
Disease control Recruiting nowThis phase II trial tests whether taking leucogen alongside standard ribociclib therapy can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone-positive breast cancer. About 94 participants will receive the combination and be mon…
Matched conditions: HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo aims to stop breast cancer return after chemo
Disease control Recruiting nowThis phase III trial tests whether adding ribociclib to standard hormone therapy (aromatase inhibitor) can prevent breast cancer from coming back in women with hormone receptor-positive, HER2-negative early breast cancer who still have cancer after initial chemotherapy. About 446…
Matched conditions: HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC